anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stereotactic ablative body radiotherapy (SABR) offers the ability to deliver a high dose of radiotherapy accurately to small tumours. It is an established, effective, non-invasive treatment option for early lung cancers as an alternative to surgery and in the treatment of limited spread of cancer (called oligo-metastatic disease) in the context of clinical trials (CORE, SARON, ABC-07 etc.). In order to deliver a high dose of radiation without damaging the surrounding structures, an accurate map of the tumour and the surrounding organs and their relationship to each other when moving (for e.g. during breathing) is important. This is usually achieved by getting a radiotherapy treatment planning 4 dimensional CT scan (4D-CT). When either the tumour or organ around them (like the lung) are moving excessively it becomes difficult to target the radiation beams and often the only solution is to treat a larger volume which covers the extent of the movement. Treating larger volumes often leads to more toxicity to the surrounding tissues.Therefore managing motion is critical to increasing tumour control probability (TCP) and reducing normal tissue complication probability (NTCP). In this context, the question of reducing the movement caused by breathing, of tumours in the lower lung and upper abdomen (like the liver, adrenals, kidney etc) is an area of intense interest. Various technical and physical methods exist to help improve motion management in patients under going radiotherapy. By limiting the movement, the target volume is smaller and this enables treatment of the tumour to high doses with lesser toxicity as some of the toxicity of radiotherapy is proportionate to the volume treated i.e. lower the volume of treatment lesser the risk of toxicity.

Abdominal compression is one such method and is well accepted to be beneficial in reducing tumour motion.

However, many of the previous studies require expensive and resource intensive immobilisation devices, costing, in many cases in excess of £10,000. This study will investigate the use of an independent compression device which can be used with any existing immobilisation system and costs in the region of £1,500. If proven to be beneficial this will allow many smaller centres or centres with budget limitations to also achieve the benefits of abdominal compression without extensive resource and cost requirements.
PURPOSE: Subdural hemorrhage along the optic nerve (ON) is a histopathological indicator of abusive head trauma (AHT) in infants. We sought to determine if this bleeding could be caused by an abrupt increase in intracranial pressure transmitted to cerebrospinal fluid (CSF) at the optic foramen (OF).
METHODS: A theoretical model is developed to simulate the effect of a pressure perturbation of maximal amplitude P applied at the optic foramen for a short duration T on the CSF-filled ON subarachnoid space (ONSAS). The ONSAS is modelled as a fluid-filled channel with an elastic wall representing the flexible ONSAS-arachnoid/dura interface. A constitutive law describing the relationship between CSF pressure and ONSAS deformation is inferred from published measurements. CSF pressure profiles along the ONSAS are examined systematically over a broad range of P and T.
RESULTS: The pressure perturbation initiated at the OF produces a pressure wave that stretches the ONSAS. This wave propagates rapidly along the ONSAS toward the scleral end of the ON, where it is reflected back toward the brain. For sufficiently small T a shock wave with amplification up to six times larger than P over a timescale of tens of milliseconds is observed at the scleral end of the ON. Comparatively smaller amplifications are observed for slower perturbations.
CONCLUSIONS: A sudden increase in CSF pressure in the cranial cavity can cause a rapid expansion of the ONSAS, which may lead to rupture of the bridging blood vessels. Our study predicts a plausible mechanism for subdural hemorrhage that occurs in abusive head trauma in infants.
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor.

Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.
<P>PROBLEM TO BE SOLVED: To easily store and take out a medical chart.  <P>SOLUTION: When taking out the medical chart, a host computer 1 specifies a shelf number of a medical chart storage shelf 10 corresponding to a patient ID read from a magnetic card 6 by a card reader/writer 2 to turn on a light emitting device on the shelf of the shelf number by controlling a control device 4. When it becomes clear that the medical chart is taken out from the result of a communication with a RFID label 8 attached to the medical chart, the light emitting device is turned off. When storing the medical chart, the host computer 1 specifies the shelf number of the medical chart storage shelf 10 corresponding to the patient ID and controls the control device 4 to turn on the light emitting device on the shelf of the shelf number. When it becomes clear that the medical chart is stored from the result of the communication with the RFID label 8 attached to the medical chart, the light emitting device is turned off.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The nurses who were informed about the study and agreed to participate in the study will be followed by two observers at the same time and filled in the "Blood Pressure Measurement Observation Form". Nurses will not be informed by whom and when they will be observed. Each observer will observe each nurse three times (1st observation). After the first observation is over, the "Blood Pressure Knowledge Test" will be applied to the nurses (Pre-test). Then, the training program prepared by the researcher will be uploaded to the hospital automation system and nurses will be asked to follow it. In addition, nurses will be able to log in to the training module and watch the video again and again whenever they want. Nurses will be given a two-week period to follow the training module. At the end of two weeks, the nurses will fill out the "Blood Pressure Information Test" again (2nd test). The "Blood Pressure Measurement Observation Form" will be filled in by the researcher during the blood pressure measurement of the nurses again in the form of the final follow-up (2nd observation).
From June 2019 to December 2020 in each participating center, patients with recurrent rectal cancer after surgery and radiotherapy will be included in the study if they meet the inclusion criteria and do not meet the exclusion criteria. According to the clinical conditions of the patients, they will be assigned to groups A or B according to the doctor's recommendations and their own wishes. GTV of both groups are visible tumors. The CTV of group A is expanded by 3mm on the basis of GTV, and the CTV of group B is expanded by 6mm. Both groups A and B received prescription dose: 95% GTV (120-160) Gy, 95% CTV (90-120) Gy. The activities of 125I seeds will be 0.4mCi-0.7mCi. All patients will receive 3D printed template-assisted 125I seeds implantation and be followed up. The differences in local progression-free survival time, overall survival time, change of quality of life, and side effects between different groups will be prospectively analyzed.
Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
BACKGROUND: Summarizing the clinical features of children with intussusception secondary to small bowel tumours and enhancing awareness of the disease.
METHODS: Retrospective summary of children with intussusception admitted to our emergency department from January 2016 to January 2022, who underwent surgery and were diagnosed with small bowel tumours. Summarize the types of tumours, clinical presentation, treatment, and prognosis.
RESULTS: Thirty-one patients were included in our study, 24 males and 7 females, with an age of onset ranging from 1 m to 11y 5 m. Post-operative pathology revealed 4 types of small intestinal tumour, 17 lymphomas, 10 adenomas, 4 inflammatory myofibroblastomas and 1 lipoma. The majority of tumours in the small bowel occur in the ileum (83.9%, 26/31). Abdominal pain, vomiting and bloody stools were the most common clinical signs. Operative findings indicated that the small bowel (54.8%, 17/31) and ileocolic gut were the main sites of intussusception. Two types of procedure were applied: segmental bowel resection (28 cases) and wedge resection of mass in bowel wall (3 cases). All patients recovered well postoperatively, with no surgical complications observed. However, the primary diseases leading to intussusception showed slight differences in long-term prognosis due to variations in tumor types.
CONCLUSIONS: Lymphoma is the most common cause of intussusception in pediatric patients with small bowel tumours, followed by adenoma. Small bowel tumours in children tend to occur in the ileum. Therefore, the treatment of SBT patients not only requires surgeons to address symptoms through surgery and obtain tissue samples but also relies heavily on the expertise of pathologists for accurate diagnosis. This has a significant impact on the overall prognosis of these patients.
The death and disability caused by myocardial infarction is a health problem that needs to be addressed worldwide, and poor cardiac repair and fibrosis after myocardial infarction seriously affect patient recovery. Postmyocardial infarction repair by M2 macrophages is of great significance for ventricular remodeling. Quercitrin (Que) is a common flavonoid in fruits and vegetables that has antioxidant, anti-inflammatory, antitumor and other effects, but whether it has a role in the treatment of myocardial infarction is unclear. In this study, we constructed a mouse myocardial infarction model and administered Que. We found through cardiac ultrasound that Que administration improved cardiac ejection fraction and reduced ventricular remodeling. Staining of heart sections and detection of fibrosis marker protein levels revealed that Que administration slowed fibrosis after myocardial infarction. Flow cytometry showed that the proportion of M2 macrophages in the mouse heart was increased and that the expression levels of M2 macrophage markers were increased in the Que-treated group. Finally, we identified by metabolomics that Que reduces glycolysis, increases aerobic phosphorylation, and alters arginine metabolic pathways, polarizing macrophages toward the M2 phenotype. Our research lays the foundation for the future application of Que in myocardial infarction and other cardiovascular diseases.
We present modern data on the role of superoxide dismutase (SOD) in antioxidant protection and gene regulation in acute pancreatitis. Antioxidant enzymes are essential in pathogenesis of numerous diseases. SOD is one of the key enzymes of antioxidant system. In this review, we analyzed activity of this enzyme depending on various factors, mechanisms and role in physiological and pathological processes, in particular, acute pancreatitis. SOD is significantly less active in patients with severe acute pancreatitis accompanied by renal failure, severe circulatory disorders and high mortality. There are some SOD gene polymorphisms, in particular, acute destructive pancreatitis R213G, contributing to acute inflammation. Thus, SOD is not only one of the key antioxidant enzymes, but also potential transcription factor regulating activity of signaling pathways. These aspects can underlie new therapies for diseases.
The present invention is to provide a pantyliner for relieving dysmenorrhea of women. The pantyliner includes a skin contact layer and an inner layer. The skin contact layer and the inner layer are two layers formed of medical non-woven fabric. A medicine bag is positioned between the skin contact layer and the inner layer, and is manufactured by attaching and compressing powder to a traditional Chinese medicine volatile oil bag with hydrosol. In addition, the traditional Chinese medicine volatile oil bag comprises: 1.8-2.5 parts by weight of a traditional Chinese medicine volatile oil composition; and 6-20 parts by weight of starch. Furthermore, the traditional Chinese medicine volatile oil composition includes the following traditional Chinese volatile oil: 4-10 parts by weight of safflower oil; 4-10 parts by weight of Ligusticum wallichii oil; 4-10 parts by weight of Rehmannia glutinosa oil; and 1-2 parts by weight of pseudo-ginseng oil.
Foam roller massage will be applied to the thoracolumbar posterior chain for participants in the myofascial release and exercise group. At the same time, balance training, squat exercises, reach forward with sitting and hamstring stretching exercises will be applied to this group for a period of four weeks. Before starting the exercise training programs, a 5 minute warm-up will be done. The first evaluation of the participants will be made before starting the 4-week program. Final assessments will be made within 2-3 days after the 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
The invention relates to a valsartan amlodipine pharmaceutical composition and a preparation method thereof. The pharmaceutical composition is composed of the following formula: 5 parts by weight of amlodipine besylate, 80 parts by weight of valsartan, 20-50 parts by weight of lactose, 10-40 parts by weight of microcrystalline cellulose, 3-6 parts by weight of low substituted hydroxypropyl cellulose, 0.3-2 parts by weight of silica and 0.5-5 parts by weight of sodium stearyl fumarate. The pharmaceutical composition is prepared from a direct powder compression process. The invention adopts a small amount of disintegrating agent to reach dissolution of more than 90%, and the composition has the advantages of good stability and fast disintegration. The preparation method provided by the invention has simple production process, reduces the corresponding investment in equipment factory, and saves the production cost. The tablet produced by the direct powder compression has faster disintegration, and helps to improve the dissolution of the drug; and through test, the tablet prepared by the method of the invention has dissolution above 90% in 15 min.
The invention discloses application of a substance for inhibiting activity and/or expression quantity of CWF19L1 protein in inhibiting RSV replication. The substance inhibiting the activity and/or the expression level of the CWF19L1 protein consists of the sequence represented by SEQ ID NO:4 and the single stranded nucleic acid molecule shown in SEQ ID NO: 5. After RSV infection of cells or mice, the content of CWF19L1 protein was significantly reduced; the CWF19L1 protein knockdown can inhibit RSV replication and improve survival rate of infected cells; CWF19L1 protein also inhibits IL-8 secretion. In addition, overexpression of CWF19L1 was also found to be able to induce autophagosome production. Thus, the CWF19L1 protein participates in the RSV replication, inflammation and autophagy-related processes, and the substance inhibiting the activity and/or expression level of the CWF19L1 protein can prevent and/or treat diseases caused by RSV. The invention has important application value.
BACKGROUND: Autoantibodies against the potassium voltage-gated channel subfamily A member 2 (KCNA2) have been described in a few cases of neuropsychiatric disorders, but their diagnostic and pathophysiological role is currently unknown, imposing challenges to medical practice.
DESIGN / METHODS: We retrospectively collected comprehensive clinical and paraclinical data of 35 patients with KCNA2 IgG autoantibodies detected in cell-based and tissue-based assays. Patients' sera and cerebrospinal fluid (CSF) were used for characterization of the antigen, clinical-serological correlations, and determination of IgG subclasses.
RESULTS: KCNA2 autoantibody-positive patients (n = 35, median age at disease onset of 65 years, range of 16-83 years, 74 % male) mostly presented with cognitive impairment and/or epileptic seizures but also ataxia, gait disorder and personality changes. Serum autoantibodies belonged to IgG3 and IgG1 subclasses and titers ranged from 1:32 to 1:10,000. KCNA2 IgG was found in the CSF of 8/21 (38 %) patients and in the serum of 4/96 (4.2 %) healthy blood donors. KCNA2 autoantibodies bound to characteristic anatomical areas in the cerebellum and hippocampus of mammalian brain and juxtaparanodal regions of peripheral nerves but reacted exclusively with intracellular epitopes. A subset of four KCNA2 autoantibody-positive patients responded markedly to immunotherapy alongside with conversion to seronegativity, in particular those presenting an autoimmune encephalitis phenotype and receiving early immunotherapy. An available brain biopsy showed strong immune cell invasion. KCNA2 autoantibodies occurred in less than 10 % in association with an underlying tumor.
CONCLUSION: Our data suggest that KCNA2 autoimmunity is clinically heterogeneous. Future studies should determine whether KCNA2 autoantibodies are directly pathogenic or develop secondarily. Early immunotherapy should be considered, in particular if autoantibodies occur in CSF or if clinical or diagnostic findings suggest ongoing inflammation. Suspicious clinical phenotypes include autoimmune encephalitis, atypical dementia, new-onset epilepsy and unexplained epileptic seizures.
A hand-held RFID scanner appliance is employed to capture and display status of urinary catheters in hospital patients. The patients are provided with RFID wrist bracelets, and catheters are provided with RFID tags, each with a unique identification code. When the nurse performs a catheter insertion, the nurse scans the patient wrist bracelet with the appliance, then scans a selected catheter. After the catheter is successfully inserted, the catheter is scanned a second time. This creates a time stamp, and a data entry is recorded with the patient identity, presence of catheter, and time of insertion. The appliance is synchronized to the hospital server, and the catheterization status of the hospital patients is displayed for the medical practitioners. This process aids in preventing hospital-acquired urinary tract infections.
The experimental group (EG) that after an initial evaluation will be subjected to a physical training program based on the ERFS, for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 30-45 min per session. Once the intervention is finished, a final evaluation will be used again to see if there is a difference or not with the results obtained at the beginning.
Single or multiple injections of holmium-166 microspheres (up to 150 Gy) in a single session. Intervention is not repeated.
One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
PURPOSE:To provide a thrombolytic agent composed of a tissue plasminogen activator and arginine or its acid addition salt. CONSTITUTION:A thrombolytic agent is produced by compounding tissue plasminogen activator (t-PA: having high affinity to thrombus and excellent thrombolytic capability compared with urokinase) with >=1mM, preferably 5-200mM of arginine or its acid addition salt. It is preferably administered in the form of injection. The agent may be incorporated with a diluent, stabilizer, etc., such as albumin, mannitol, etc., in addition to the t-PA used as a main component. EFFECT:The addition of arginine enables the increase of t-PA concentration. Accordingly, a large amount of t-PA can be filled in a small vial or ampule, etc., to enable effective therapeutic treatment.
Participation will be for six months. Participants will meet staff at three timepoints (baseline, 3 months, 6 months) to complete questionnaires, online dietary assessment, body measures, have blood pressure measured, provide blood and stool samples, and wear an activity monitor for a week at each time point.
Objective: To explore the feasibility of integrating sleep management interventions with dietary and exercise interventions for obesity in a 12-week randomized trial. Methods: We randomized 49 overweight or obese adult patients either to a better weight (BW) cognitive behavioral intervention, or to a combination of the BW intervention and a better sleep intervention, better weight-better sleep (BWBS). Results: The BWBS group lost weight faster (P=.04), and coping self-efficacy accelerated (P=.01). Conclusions: These preliminary results merit replication in a larger primary care-based trial with a longer continuous intervention and followup period. Key words: obesity, sleep, weight loss, primary care, health behavior E Logue et al. Am J Health Behav. 2012;36(3):319-334 DOI: http://dx.doi.org/10.5993/AJHB.36.3.4